PBMTC SUP1701, Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES)
Study ID: STU 052018-016
The primary purpose of this pilot study is to assess the safety and feasibility of administering partially HLa-matched VSTs in transplant or PiD patients with eBV, CMV, and/or adenovirus infection refractory to standard therapy. Following study enrollment, high-resolution HLa typing of the patient and HSCT donor (if applicable) will be sent to Children's national Medical Center along with details regarding the targeted virus(es), and an inquiry of the VST bank will be performed to determine if a partially HLa-matched VST product exists that has antiviral activity against the targeted virus(es) mediated through one or more shared HLa alleles.
This phase i/ii trial is designed to evaluate the feasibility, safety and anti-viral activity of partially HLa-matched VSTs for treatment of persistent eBV, CMV, and/or adenovirus infections in patients who have undergone HSCT, or in patients with PiD who have not undergone HSCT.